Table 3.
Summary of αS pathology, microgliosis, and astrogliosis in each mouse line assessed for pathology induction with respective inoculums
| Type of Inoculum | αS Pathology | Microgliosis | Astrogliosis | |
|---|---|---|---|---|
| nTg | PBS | – | +/− | +/− |
| nTg | Control Lysate | – | +/− | +/− |
| nTg | MSA Lysate | – | +/− | +/− |
| M20+/− | PBS | – | +/− | +/− |
| M20+/− | Control Lysate | – | +/− | +/− |
| M20+/− | MSA Lysate | – | +/− | +/− |
| M83+/− | PBS | – | +/− | +/− |
| M83+/− | Control Lysate | – | +/− | +/− |
| M83+/− | MSA Lysate | +++ | ++ | +++ |
| M83+/− | WT αS Fibrils | + | + | ++ |
| M83+/− | A53T αS Fibrils | ++ | + | ++ |
For each mouse line, qualitative neuropathological grading of pathological inclusion burden and immunological response induced by each inoculum was graded on the following scale: (+/−) rare, (+) mild, (++) moderate, and (+++) severe. This grading for M83+/− injected with MSA lysates only include the mice that developed αS inclusion pathology